SPOTLIGHT: Will Rituxan be next MS breakthrough?


The cancer drug Rituxan cut multiple sclerosis lesions and relapses in a small clinical trial; its developers, Genentech and Biogen Idec, hope to establish its efficacy in larger trials. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.